Celyad Oncology Discontinues Autologous CAR T Candidate CYAD-01; CYCLE-1 CYAD-02 Trial Ongoing

Celyad Oncology SA (CYAD), a clinical-stage biotechnology company focused on chimeric antigen receptor T cell or CAR T therapies for cancer, issued Monday updates on allogeneic and autologous CAR T Programs.

The updates from the company's shRNA-based anti-B cell maturation antigen or BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates, CYAD-01 and CYAD-02, were virtually presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

The company said it is disappointed in its update from the Phase 1 THINK trial for first-generation, autologous CAR T candidate CYAD-01 and discontinues its development based on clinical futility observed to date from the Phase 1 THINK trial.

Meanwhile, preliminary data from CYCLE-1 trial evaluating next-generation autologous CYAD-02 in r/r AML / MDS patients showed encouraging clinical signals, including a high-risk MDS patient treated at dose level 3 who achieved an objective marrow complete response. The company said dose level 3 cohort of the CYCLE-1 trial is ongoing.

The company noted the dosing of first patient with CYAD-211 Phase 1 IMMUNICY-1 trial. Preclinical results for CYAD-211 for multiple myeloma showed robust antitumor activity with no demonstrable evidence of Graft-versus-Host Disease.

Filippo Petti, Chief Executive Officer of Celyad Oncology, said, "While we are disappointed by the latest update from the Phase 1 THINK trial for CYAD-01, we are encouraged by the initial clinical results from our next-generation CYAD-02 candidate for the treatment of patients with relapsed or refractory AML and MDS and look forward to future updates from the CYCLE-1 trial."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, Inc., a privately held food company, is recalling certain chocolate products containing recalled Jif peanut butter due to the potential for salmonella contamination, the U.S. Food and Drug Administration said. The recall involves 795, 8-ounce boxes of Wilbur brand products, such as Milk and Dark Chocolate Covered Peanut Butter Ritz Crackers, Peanut Butter Meltaways... The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab) to treat eosinophilic esophagitis or EoE, a chronic immune disorder. It is the first FDA approval to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms. Food products maker J. M. Smucker Co. has recalled select Jif peanut butter products sold in the United States due to potential Salmonella contamination, the U.S. Food and Drug Administration said. The recall involves various creamy, crunchy, natural, no added sugar, and reduced fat peanut butter, among others with lot codes 1274425 - 2140425.
Follow RTT